Brilinta Clinical Experience Investigation

  • End date
    Mar 30, 2028
  • participants needed
  • sponsor
Updated on 22 November 2020
AstraZeneca Clinical Study Information Center
Primary Contact
Research Site (0.7 mi away) Contact
+31 other location


To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase.

  1. Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on bleeding, dyspnoea and bradyarrhythmia so as to investigate onset, outcome, treatment for the event, and risk factors for these events, etc.
  2. Profile and incidence of ADRs not expected from "Precautions for Use" of the ticagrelor JPI
  3. Efficacy: Profile and incidence of cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke)
  4. Factors which may affect safety or efficacy of ticagrelor

Clinical Study IdentifierNCT03212287
Last Modified on22 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age between 16 yrs and 130 yrs?
Gender: Male or Female
Do you have Acute Coronary Syndrome, Old Myocardial Infarction?
Do you have any of these conditions: Do you have Acute Coronary Syndrome, Old Myocardial Infarction??
Do you have any of these conditions: Do you have Acute Coronary Syndrome, Old Myocardial Infarction??
Patients treated with BRILINTA for ACS or OMI, which is the indication of the drug

Exclusion Criteria

Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet